anti-doping analysis raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-01-15 and is reviewed periodically as new material appears.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Prohibited in sport | Listed by WADA under peptide hormones |
| WADA class | S2 | Peptide hormones, growth factors, related substances, and mimetics |
| Approved therapeutic use | Not established | Clinical research did not lead to broad marketing approval |
| Common detection method | LC-MS/MS | Liquid chromatography-tandem mass spectrometry |
| Sample preparation | Extraction and enrichment | Immunoaffinity or solid-phase extraction may be used |
===== MeSH D08.811.520.241 – carbon-oxygen lyases (EC 4.2) ===== MeSH D08.811.520.241.225 – DNA-(apurinic or apyrimidinic site) lyase MeSH D08.811.520.241.300 – hydro-lyases MeSH D08.811.520.241.300.050 – aconitate hydratase MeSH D08.811.520.241.300.050.500 – iron regulatory protein 1 MeSH D08.811.520.241.300.050.750 – iron regulatory protein 2 MeSH D08.811.520.241.300.150 – carbonic anhydrases MeSH D08.811.520.241.300.150.100 – carbonic anhydrase i MeSH D08.811.520.241.300.150.200 – carbonic anhydrase ii MeSH D08.811.520.241.300.150.300 – carbonic anhydrase iii MeSH D08.811.520.241.300.150.400 – carbonic anhydrase iv MeSH D08.811.520.241.300.150.500 – carbonic anhydrase v MeSH D08.811.520.241.300.200 – cystathionine beta-synthase MeSH D08.811.520.241.300.250 – enoyl-coa hydratase MeSH D08.811.520.241.300.300 – fumarate hydratase MeSH D08.811.520.241.300.500 – phosphopyruvate hydratase MeSH D08.811.520.241.300.500.500 – tau-crystallins MeSH D08.811.520.241.300.550 – porphobilinogen synthase MeSH D08.811.520.241.300.600 – prephenate dehydratase MeSH D08.811.520.241.300.650 – propanediol dehydratase MeSH D08.811.520.241.300.850 – tryptophan synthase MeSH D08.811.520.241.300.900 – urocanate hydratase MeSH D08.811.520.241.300.950 – uroporphyrinogen iii synthetase MeSH D08.811.520.241.700 – polysaccharide-lyases MeSH D08.811.520.241.700.350 – chondroitinases and chondroitin lyases MeSH D08.811.520.241.700.350.500 – chondroitin lyases MeSH D08.811.520.241.700.350.500.500 – chondroitin abc lyase MeSH D08.811.520.241.700.512 – heparin lyase MeSH D08.811.520.241.700.675 – hyaluronoglucosaminidase
The most commonly performed 15N experiment is the 1H-15N HSQC. The experiment is highly sensitive and therefore can be performed relatively quickly. It is often used to check the suitability of a protein for structure determination using NMR, as well as for the optimization of the sample conditions. It is one of the standard suite of experiments used for the determination of the solution structure of protein. The HSQC can be further expanded into three- and four dimensional NMR experiments, such as 15N-TOCSY-HSQC and 15N-NOESY-HSQC.
=== Reliability === Shock resistance: LEDs, being solid-state components, are difficult to damage with external shock, unlike fluorescent and incandescent bulbs, which are fragile. Thermal runaway: Parallel strings of LEDs will not share current evenly due to the manufacturing tolerances in their forward voltage. Running two or more strings from a single current source may result in LED failure as the devices warm up. If forward voltage binning is not possible, a circuit is required to ensure even distribution of current between parallel strands. Slow failure: LEDs mainly fail by dimming over time, rather than the abrupt failure of incandescent bulbs. Lifetime: LEDs can have a relatively long useful life. One report estimates 35,000 to 50,000 hours of useful life for white LEDs, though time to complete failure may be shorter or longer. Fluorescent tubes typically are rated at about 10,000 to 25,000 hours, depending partly on the conditions of use, and incandescent light bulbs at 1,000 to 2,000 hours. Several DOE demonstrations have shown that reduced maintenance costs from this extended lifetime, rather than energy savings, is the primary factor in determining the payback period for an LED product. Cycling: LEDs are ideal for uses subject to frequent on-off cycling, unlike incandescent and fluorescent lamps that fail faster when cycled often, or high-intensity discharge lamps (HID lamps) that require a long time to warm up to full output and to cool down before they can be lighted again if they are being restarted.
Sources: en.wikipedia.org
=== Advantage === Komagataella is able to grow on simple, inexpensive medium, with high growth rate. Komagataella can grow in either shake flasks or a fermenter, which makes it suitable for both small- and large-scale production. Komagataella has two alcohol oxidase genes, Aox1 and Aox2, which include strongly inducible promoters. These two genes allow Komagataella to use methanol as a carbon and energy source. The AOX promoters are induced by methanol, and repressed by glucose. Usually, the gene for the desired protein is introduced under the control of the Aox1 promoter, which means that protein production can be induced by the addition of methanol on medium. After several researches, scientists found that the promoter derived from AOX1 gene in Komagataella is extremely suitable to control the expression of foreign genes, which had been transformed into the Komagataella genome, producing heterologous proteins. With a key trait, Komagataella can grow with extremely high cell density on the culture. This feature is compatible with heterologous protein expression, giving higher yields of production. Komagataella has a well-developed secretory pathway involving the Endoplasmic reticulum and a stacked Golgi apparatus, which is more similar to those of higher eukaryotes to that of Saccharomyces cerevisiae. This enables the efficient folding and post-translational modification of heterologous proteins, including the formation of disulfide bonds and glycosylation.
Insulin-like growth factor 2 receptor (IGF2R), also called the cation-independent mannose-6-phosphate receptor (CI-MPR) is a protein that in humans is encoded by the IGF2R gene. IGF2R is a multifunctional protein receptor that binds insulin-like growth factor 2 (IGF2) at the cell surface and mannose-6-phosphate (M6P)-tagged proteins in the trans-Golgi network.
=== Family record book (1877) === The loss of Parisian civil records largely influenced the creation of the family record book in 1877, introduced by a circular from Jules Simon, President of the Council and Minister of the Interior. The circular explicitly referenced the Commune’s destruction, stating that “family record books will serve as a third deposit of civil records entrusted to individuals and will provide valuable information should registers be destroyed.” The law of April 5, 1884, concerning municipal organization, required town halls to budget for the costs of family record books.
Sources: en.wikipedia.org
== External links == Overview at colostate.edu Secretin at the U.S. National Library of Medicine Medical Subject Headings (MeSH) Nosek TM. "Section 6/6ch2/s6ch2_17". Essentials of Human Physiology. Archived from the original on 2016-03-24.
LSD was first synthesized on November 16, 1938 by Swiss chemist Albert Hofmann at the Sandoz Laboratories in Basel, Switzerland as part of a large research program searching for medically useful ergot alkaloid derivatives. LSD was synthesised from lysergic acid, a chemical derived from the hydrolysis of the alkaloid ergotamine, which can be found in the grain-infecting fungus ergot. It was the 25th substance of various lysergamides that Hofmann synthesized from lysergic acid while trying to develop a new analeptic, hence its alternate name, LSD-25.
Due to the dynamic nature of O-GlcNAc and its presence on serine and threonine residues, O-GlcNAcylation is similar to protein phosphorylation in some respects. While there are roughly 500 kinases and 150 phosphatases that regulate protein phosphorylation in humans, there are only 2 enzymes that regulate the cycling of O-GlcNAc: O-GlcNAc transferase (OGT) and O-GlcNAcase (OGA) catalyze the addition and removal of O-GlcNAc, respectively. OGT utilizes the sugar nucleotide UDP-GlcNAc as the donor sugar for transfer. First reported in 1984, this post-translational modification has since been identified on over 9,000 proteins in H. sapiens. Numerous functional roles for O-GlcNAcylation have been reported including crosstalking with serine/threonine phosphorylation, regulating protein-protein interactions, altering protein structure or enzyme activity, changing protein subcellular localization, and modulating protein stability and degradation. Numerous components of the cell's transcription machinery have been identified as being modified by O-GlcNAc, and many studies have reported links between O-GlcNAc, transcription, and epigenetics. Many other cellular processes are influenced by O-GlcNAc such as apoptosis, the cell cycle, and stress responses. As UDP-GlcNAc is the final product of the hexosamine biosynthetic pathway, which integrates amino acid, carbohydrate, fatty acid, and nucleotide metabolism, it has been suggested that O-GlcNAc acts as a "nutrient sensor" and responds to the cell's metabolic status.
== Processing == The first commercial process by which opiates are extracted from poppy straw was invented in Hungary by János Kabay. This process, known as the "poppy straw method", remains in use today. Kabay applied his new process initially to fields of opium poppies between the stages of flowering and maturity, while the fruits were green. This had several disadvantages: the immature poppy seeds could not be winnowed, so not only was the seed crop lost but their poppyseed oil interfered with the process; the abundant chlorophyll in the green plants also interfered; and an entire year's crop had to be processed in two months, as it reached the fruit stage. Kabay soon found that the process could be applied to poppy straw residue from the poppy seed harvest, thereby eliminating all these disadvantages. Poppy straw is first pulverized, then washed as many as six to ten or more times in water which may have an acid added to increase solubility, to produce poppy straw concentrate (PSC, also known as concentrate of poppy straw, CPS). Dried, the concentrate is a beige to brown powder. It contains salts of various alkaloids, and can range from nine to 30 times the morphine concentration of poppy straw. Opium concentrates using solvents other than acidifed or plain water are often but not necessarily called PSC. Poppies of the Norman and Przemko strains contain much higher amounts of thebaine (also known as paramorphine) and oripavine and have morphine concentrations from as low as below 1% up to 26% that of high-morphine strains.
Sources: en.wikipedia.org
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.
Confirmatory detection typically uses liquid chromatography with mass spectrometry. Immunoassays may be used for screening, but mass spectrometry provides structural confirmation.
No widely approved therapeutic indication exists for AOD-9604. It has been investigated in clinical studies, but regulatory approvals for general medical use are not established.
It is proposed to promote lipolysis in fat tissue, the breakdown of stored fat into fatty acids and glycerol. The detailed receptor and signaling mechanisms are not fully established.